Immune-based monitoring for cytomegalovirus infection in solid organ transplantation: is it ready for clinical primetime?

Simple item page
dc.contributor.authorDante P. Melendez
dc.contributor.authorRaymund R. Razonable
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T21:04:28Z
dc.date.available2026-03-22T21:04:28Z
dc.date.issued2014
dc.descriptionCitaciones: 16
dc.description.abstractThe impact of CMV infection and disease in solid organ transplant (SOT) recipients continues despite remarkable improvements in its prevention and management with antiviral drugs. Studies that have investigated the host immune response to CMV have paved way for the development of novel immune-based assays that are anticipated to complement the current antiviral-based strategies for CMV management after transplantation. In this article, we review the emerging data on the clinical application of innovative CMV-specific T-cell assays, including their role in risk-stratification, prognostication, prevention and treatment of CMV infection and disease in SOT recipients.
dc.identifier.doi10.1586/1744666x.2014.943190
dc.identifier.urihttps://doi.org/10.1586/1744666x.2014.943190
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/85773
dc.language.isoen
dc.publisherTaylor & Francis
dc.relation.ispartofExpert Review of Clinical Immunology
dc.sourceMayo Clinic
dc.subjectMedicine
dc.subjectCytomegalovirus
dc.subjectImmunology
dc.subjectTransplantation
dc.subjectImmune system
dc.subjectOrgan transplantation
dc.subjectCytomegalovirus infection
dc.subjectDisease
dc.subjectValganciclovir
dc.subjectInfectious disease (medical specialty)
dc.titleImmune-based monitoring for cytomegalovirus infection in solid organ transplantation: is it ready for clinical primetime?
dc.typereview

Files

Collections

Artículo Científico Publicado